Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Wed, 27.09.2023
Evotec SE
LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT BIOTECH INNOVATORS THROUGH CRITICAL INFLECTION POINTS
AGREEMENT LEVERAGES EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM TO ENABLE GREATER ACCESS TO INDUSTRY-GRADE CAPABILITIES AND DRUG HUNTING EXPERTISE FOR LIFE SCIENCES AND BIOTECH STARTUPS ACROSS THE GLOBAL LABCENTRAL / [ … ]
Tue, 26.09.2023
Evotec SE
LAB eN² WILL INVOLVE INSTITUTIONS INCLUDING HARVARD UNIVERSITY, MASS GENERAL BRIGHAM, AND BETH ISRAEL DEACONESS MEDICAL CENTER
FOCUS OF THE COLLABORATION IS TO ACCELERATE THE TRANSLATION OF ACADEMIC IDEAS TO THERAPEUTIC PRODUCT CANDIDATES IN THE CARDIOMETABOLIC SPACE
Hamburg, Germany, and Cambridge, Mass., USA, 26 September 2023:
Evotec SE (Fr [ … ]
Tue, 29.08.2023
Evotec SE
NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIAL
NEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMED
Hamburg, Germany, 29 August 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results and corporate updates for the first half-year of 2023.HIGHLIGHTS Q2 CYBER-INCIDENT [ … ]
Tue, 22.08.2023
Evotec SE
Hamburg, Germany, 22 August 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conferenc [ … ]
Thu, 27.07.2023
Evotec SE
Hamburg, Germany, 27 July 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack.
For the current fiscal year, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 [ … ]
Thu, 27.07.2023
Evotec SE
Hamburg, Germany, 27 July 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack.
For the current fiscal year, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 [ … ]
Thu, 27.07.2023
Evotec SE
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it is adjusting its guidance for the fiscal year 2023.
Due to the impact of the cyber-attack, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 – 840 m); unpa [ … ]
Thu, 27.07.2023
Evotec SE
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it is adjusting its guidance for the fiscal year 2023.
Due to the impact of the cyber-attack, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 – 840 m); unpa [ … ]
Tue, 11.07.2023
Evotec SE
EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION
SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS
EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN PERFORMANCE MILESTONE PAYMENTS, AS WELL AS TIERED ROYALT [ … ]
Tue, 11.07.2023
Evotec SE
EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION
SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS
EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN PERFORMANCE MILESTONE PAYMENTS, AS WELL AS TIERED ROYALT [ … ]